Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Research runs each weekday at 8 a.m. Eastern Time. Channels update when qualifying developments are found. Editorial standards · RSS ↗
Moderna reported that its Phase 3 safety and efficacy trial of the norovirus vaccine candidate mRNA-1403 did not meet the statistical criteria for early success at an interim analysis. The study remains ongoing and blinded, and the company is preparing to enroll another cohort. The announcement does not establish the final efficacy result or show that the entire trial has failed.
Researchers identified Klebsiella phage 32 RNA polymerase as an alternative to T7 for RNA production. The enzyme tolerated a broad range of temperatures, pH values, and salt conditions. For an 11,551-nucleotide self-amplifying RNA retaining its native AU initiation, production was 9.3-fold higher than the T7 comparison. These laboratory results do not establish GMP-scale performance.
Comparing intranasal and intratracheal vaccination, researchers found that total lung expression alone poorly predicted functional delivery to alveolar macrophages. Intratracheal mRNA-LNP delivery produced stronger macrophage transfection and antigen presentation, with improved tumor control in pulmonary models. Depleting alveolar macrophages eliminated protection, supporting their mechanistic role. These administration and efficacy findings remain preclinical.
Across six ionizable lipids, researchers encapsulated RNAs ranging from short oligonucleotides to 4.5-kilobase mRNA and measured apparent pKa using a fluorescence assay. Both RNA length and structure altered particle ionization, with lipid-dependent shifts. The study indicates that cargo is an active formulation variable; it does not directly establish changes in therapeutic efficacy or organ targeting.
A Coxsackievirus B5 replicon used internal ribosome entry site-driven translation to generate a capless self-amplifying RNA vaccine. Genetic optimization improved expression, and LNP-formulated H5 antigen constructs induced neutralizing antibodies and cellular responses in mice. Low-dose vaccination protected against lethal H5N8 challenge. The platform changes capping requirements, but human immunogenicity, manufacturing performance, and safety remain unestablished.
Vilya-2 extends the company’s all-atom representation from individual molecules to interactions with protein targets using a diffusion-transformer model. The preprint focuses on noncanonical residues, macrocyclization, and complex topologies. Company examples include modeling icotrokinra and enlicitide complexes. Structural predictions support discovery hypotheses rather than proving oral exposure or clinical activity for newly designed candidates.
This review examines mRNA therapy and impurity control during in vitro transcription, focusing on purification strategies and double-stranded RNA removal. It compares detection and separation approaches with attention to RNA integrity, recovery, and manufacturing feasibility. Construct-specific differences and analytical limitations complicate direct comparisons; the review does not establish a universal acceptable dsRNA limit for every product.
Researchers removed individual components from mRNA-LNP formulations to distinguish the contributions of ionizable lipid, cholesterol, phospholipid, and PEG-lipid. Animal experiments linked these components differently to liver delivery, extrahepatic expression, particle size, and inflammation. The results challenge uniform assumptions about helper-lipid functions, while remaining dependent on the specific formulations and experimental systems tested in this study.
Chugai reported that AQUA07, its third macrocyclic peptide project, had entered the clinical stage, with Phase 1 dosing in ALK-positive non-small cell lung cancer expected shortly. Its pipeline identifies AQUA07 as an oral allosteric ALK inhibitor originating from SnipeTide. The milestone does not establish that human efficacy has already been demonstrated.
Nine bile-acid-derived sterols varied hydroxylation and alkyl-tail chemistry to probe LNP organization and organ expression. Molecular simulations and experiments linked membrane descriptors with encapsulation and formulation behavior. Replacing cholesterol shifted expression toward the spleen, and a lead sterol enhanced antigen-specific responses. The work offers a preclinical formulation framework rather than validated prediction of human biodistribution.
Immunomic announced first-patient dosing in VITALITI, the first-in-human Phase 1 trial of ITI-5000, a self-amplifying RNA cancer vaccine. The open-label study evaluates safety, tolerability, and preliminary immune activity in stage II–III triple-negative breast cancer, alone or alongside standard adjuvant therapy. Initial monitoring of the first participant identified no significant safety concerns, but this milestone provides no efficacy evidence.
Bispecific antibodies were used to bridge PEG motifs on LNPs and selected cellular surface markers without elaborate chemical conjugation. The platform enabled targeted mRNA delivery in cell models and transferrin-receptor-associated delivery in vivo. Researchers also measured endosomal responses at different antibody-loading ratios. Splenic enrichment supports further immune-cell targeting studies, but does not establish a clinical delivery solution.
All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.
